At the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California, Robert J. Motzer, MD, presented results from the phase 3 LITESPARK-011 trial (NCT04586231), evaluating the combination of belzutifan (Welireg) plus lenvantinib (Lenvima) vs cabozantinib (Cabometyx) in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC).1 Motzer, section head, Kidney Cancer, Genitourinary Oncology Service and the Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center in New York, New York, discussed the rationale for exploring this novel combination and its potential role after progression on immunotherapy-based regimens.
